Abstract | AIM: METHODS: We retrospectively undertook exploratory data analyses comparing patient- and treatment-related factors in patients with (N.=48) and without (N.=520) all-cause amputation. RESULTS: Of the amputation cases, 46% had received warfarin, and 97.9% had severe ischemia/ gangrene diagnosed pre- argatroban. Thromboembolic complications prior to argatroban were more common in amputation cases (91.7% vs. 71.9%, P=0.003), with a higher proportion of arterial than venous events (68.2% vs. 52.3%, P=0.031; mean 1.7/patient vs. 1.4/patient, P=0.031), largely occurring in the limbs (94.1%). More females than males suffered amputation (P=0.003), and cardiovascular risk was more frequent in amputation cases than non- amputation ( hypertension, P=0.008; peripheral vascular disease (PVD), P<0.001; diabetes, P<0.001). There were no differences in baseline platelet count, platelet recovery (24 h post- argatroban), or weighted mean aPTT between groups; amputation was associated with longer treatment duration (5 vs. 7 days, P=0.001). CONCLUSION:
|
Authors | S Haas, B Lewis |
Journal | International angiology : a journal of the International Union of Angiology
(Int Angiol)
Vol. 30
Issue 6
Pg. 541-6
(Dec 2011)
ISSN: 1827-1839 [Electronic] Italy |
PMID | 22233615
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticoagulants
- Antithrombins
- Pipecolic Acids
- Sulfonamides
- Heparin
- Arginine
- argatroban
|
Topics |
- Aged
- Amputation, Surgical
(statistics & numerical data)
- Anticoagulants
(adverse effects)
- Antithrombins
(therapeutic use)
- Arginine
(analogs & derivatives)
- Chi-Square Distribution
- Clinical Trials as Topic
- Female
- Heparin
(adverse effects)
- Humans
- Male
- Middle Aged
- Multicenter Studies as Topic
- Pipecolic Acids
(therapeutic use)
- Retrospective Studies
- Risk Assessment
- Risk Factors
- Sulfonamides
- Thrombocytopenia
(chemically induced, drug therapy, surgery)
- Time Factors
- Treatment Failure
|